AstraZeneca has joined forces with not-for-profit organisation Sutter Health on a research and innovation collaboration on cardiometabolic healthcare.
The three-year partnership will work to design, prototype and pilot innovative approaches to the form of healthcare, which focuses on the treatment and management of diseases such as diabetes, hypertension and high cholesterol in addition to more common complications such as heart attack, blindness or death.
Greg Keenan, VP medical affairs and US medical officer at AZ, commented: “Diabetes, high blood pressure and poorly controlled cholesterol can have an enormous impact on a person’s quality of life and the cost of healthcare.
“We believe that Sutter Health and AZ will bring together unique expertise and experiences to improve the lives of patients.
“Through this innovative research collaboration, we hope to improve the future of cardiometabolic care and translate solutions into programmes that health systems nationwide could implement.”
Researchers will aim to help speed up diagnosis and improve the quality of life of patients by creating technologies and treatments through a better understanding of existing gaps in cardiometabolic care.
The collaboration will focus on three key areas; utilising key data from across the Sutter Health network into a electronic system and conduct novel analytical steps to identify gaps; personalising care by designing, developing and implementing new tools to help patients and providers work together; and supporting the continuous knowledge growth of researchers.